Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Akkodis and Hamburg Public Transport Association Showcase hvv mia at InnoTrans 2026, Demonstrating the Future of AI-Powered Mobility22.9.2026 06:45:00 CEST | Press release
BERLIN, DE / ACCESS Newswire / September 22, 2026 / Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, will showcase how artificial intelligence is helping transform passenger mobility at InnoTrans 2026, the world's leading international trade fair for transport technology. Headlining Akkodis' presence is hvv mia, one of Akkodis' Synergeticon solutions, developed in collaboration with Hamburg Public Transport Association (hvv) to create more seamless, accessible and connected passenger experiences. Together, Akkodis and hvv will demonstrate how AI can help transportation operators better serve passengers while advancing the digital transformation of rail and other transportation networks. Built on Akkodis' Synergeticon AI Conversational Service Hub, hvv mia is a real-world example of how conversational and agentic AI can connect information, services and transactions across transportation systems through a single natural-language interface. Develop
FQ-42 Vengeance Finds New Home at Creech Air Force Base21.9.2026 17:00:00 CEST | Press release
SAN DIEGO, CA / ACCESS Newswire / September 21, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) congratulates the U.S. Air Force (USAF) on the pace of progress for its Collaborative Combat Aircraft program, which features the FQ-42 Vengeance designed and produced by GA-ASI. The latest milestone took place Sept. 18, when a new FQ-42 Vengeance was delivered to Creech AFB, Nev., to continue operations with test and evaluation units. "The CCA program's rate of progress has been incredible," said Mike Atwood, GA-ASI Vice President of Advanced Programs. "Every week, the Air Force is pushing forward with new and more impressive accomplishments using Vengeance. It's amazing to think of how far this program has come in such a short amount of time." The FQ-42 that arrived at Creech will continue regular test and evaluation operations with the Air Force aimed at experimentation with the new aircraft. Previous efforts with Vengeance and other GA-ASI jets, including XQ-67A Off-Board Sens
Datavault AI and Cutting-Edge Sports Management Announce Dream Bowl XV at AT&T Stadium and Launch First-of-Its-Kind Bowl Combine21.9.2026 15:45:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / September 21, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced Dream Bowl XV. The game is the 15th anniversary edition of the premier college football all-star showcase for professional draft-eligible talent from all college divisions and NAIA programs. It will be held Sunday, January 17, 2027, at AT&T Stadium in Arlington, Texas, and is planned to be broadcast nationally on ESPN. Dream Bowl XV continues Datavault AI's role as an intellectual property licensing partner and official sponsor of The Dream Bowl alongside Cutting-Edge Sports Management. It builds on the Company's debut at Dream Bowl XIV. Since 2013, The Dream Bowl has honored the legacy of Dr. Martin Luther King Jr. and has given overlooked collegiate athletes a professional-caliber send-off in front of professional scouts. N
Winners of this Year's Semmelweis-Richter International Journalism Award Announced21.9.2026 14:05:00 CEST | Press release
BUDAPEST I. KERÜLET, HU / ACCESS Newswire / September 21, 2026 / For the second time, Semmelweis University, with the support of Gedeon Richter, has recognized outstanding health and science journalism from across Europe through the Semmelweis-Richter Journalism Award. Six entries received awards in the "Women's Health" and "Pharmaceutical Strategies and Innovation" categories. The first prizes in the two categories were awarded to an international investigative project on abortion and an article about a technology that uses miniature bioengineered devices to mimic the functions of human organs. The competition received around 60 entries from nearly 20 countries. The Semmelweis-Richter Journalism Award was established to recognize high-quality health and science journalism in Europe. As last year, the competition attracted entries from journalists working for major international media outlets, including The Guardian, the Financial Times, The Times, BBC News, Süddeutsche Zeitung and Púb
NOVELIC Partners with Global DMS Leader Smart Eye to Develop Next-Generation Camera and Radar In-Cabin Monitoring Systems21.9.2026 08:00:00 CEST | Press release
BELGRADE, RS / ACCESS Newswire / September 21, 2026 / NOVELIC, a Belgrade-based innovator in mmWave radar solutions, announced a strategic partnership with Smart Eye, a global leader in Driver Monitoring Systems (DMS) and Interior Sensing AI, to provide OEMs with a well-rounded feature set that satisfies the upcoming Euro NCAP requirements for driver and occupant monitoring. The result is a scalable and cost-effective solution that combines vision and radar for straightforward integration. Since the software is running entirely on the sensor, only a single CAN-Bus interface to the vehicle is required, eliminating the need for external hardware, LVDS interfaces, and added computational load elsewhere in the car. NOVELIC and Smart Eye's innovative system approach will debut at Smart Eye's booth #305 at InCabin Europe 2026 in Barcelona. The demonstration will showcase enhanced performance and compliance with relevant safety protocols through the fusion of radar and vision technologies. NO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom